Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biofrontera (BFRIW) EBITDA Margin (2020 - 2025)

Biofrontera has reported EBITDA Margin over the past 6 years, most recently at 26.66% for Q4 2025.

  • Quarterly results put EBITDA Margin at 26.66% for Q4 2025, up 4029.0% from a year ago — trailing twelve months through Dec 2025 was 27.2% (up 1891.0% YoY), and the annual figure for FY2025 was 27.21%, up 1890.0%.
  • EBITDA Margin for Q4 2025 was 26.66% at Biofrontera, up from 89.84% in the prior quarter.
  • Over the last five years, EBITDA Margin for BFRIW hit a ceiling of 26.66% in Q4 2025 and a floor of 371.6% in Q3 2021.
  • Median EBITDA Margin over the past 5 years was 59.57% (2023), compared with a mean of 75.72%.
  • Biggest five-year swings in EBITDA Margin: crashed -29952bps in 2021 and later surged 28740bps in 2022.
  • Biofrontera's EBITDA Margin stood at 20.74% in 2021, then tumbled by -165bps to 55.02% in 2022, then skyrocketed by 34bps to 36.48% in 2023, then soared by 63bps to 13.63% in 2024, then soared by 296bps to 26.66% in 2025.
  • The last three reported values for EBITDA Margin were 26.66% (Q4 2025), 89.84% (Q3 2025), and 56.25% (Q2 2025) per Business Quant data.